How long does it take to stop taking selinesol?

How long it takes to stop taking Selinexor (Selinexor) depends mainly on the patient's specific condition, treatment response and side effect management. During the treatment process, the doctor will decide whether to continue taking the medication or discontinue the treatment based on the patient's condition assessment, degree of disease relief, and tolerance of side effects. Generally, patients need to continue taking medications until clear treatment goals are achieved or until they need to be discontinued due to adverse effects.

For patients with multiple myeloma, selinexol is usually given in combination with dexamethasone, and treatment is usually twice weekly for 4 weeks. After multiple courses of treatment, if the patient achieves disease remission and side effects are controllable, the doctor may consider gradually reducing the drug dose or discontinuing the drug after the patient's condition stabilizes. However, if the patient's condition worsens during treatment or the side effects are intolerable, the medication may need to be stopped early.

Treatment duration and discontinuation criteria are generally flexible for patients with diffuse large B cell lymphoma. Depending on clinical trials and actual patient response, the duration of treatment with selinesol may be longer, usually until the patient becomes unresponsive to treatment or develops significant toxicity. In some cases, patients may need medication modifications or supportive care to alleviate side effects to extend treatment.

After stopping the drug, patients still need regular follow-up and monitoring to ensure that the condition does not relapse or worsen. If the disease progresses again, your doctor may re-evaluate treatment options, including reinstating selinesol or choosing another treatment. Patients should pay special attention to changes in their symptoms after stopping the medication and communicate with their doctors in a timely manner so that appropriate measures can be taken.

xa0

Reference materials:

https://www.ncbi.nlm.nih.gov/